Evidence map›Paper›PMID 40822998›Full record

ArticleEuropean urology open science2025

Expression of PD-L1, TIGIT, and CD155, and Human Papillomavirus Status in Patients with Advanced Penile Cancer.

Emma Ulvskog, Peter Kirrander, Erik K Persson, Gabriella Lillsunde-Larsson, Luiza Dorofte, Tania Franceschini, Michelangelo Fiorentino, Sabina Davidsson

Abstract read
In one paragraph

Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emma UlvskogDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Peter KirranderDepartment of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Erik K PerssonRegional Cancer Centre Mid Sweden, Uppsala, Sweden.
Gabriella Lillsunde-LarssonDepartment of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Luiza DorofteDepartment of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Tania FranceschiniPathology Service Maggiore Hospital, Bologna, Italy.
Michelangelo FiorentinoDepartment of Medical and Surgical Sciences, Alma Mater University of Bologna, School of Medicine, Bologna, Italy.
Sabina DavidssonDepartment of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: To improve treatment for patients with penile cancer, there is a need for prognostic and treatment predictive biomarkers. The objective of this study was to examine the expression of checkpoint proteins (programmed cell death ligand 1 [PD-L1], T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain [TIGIT], and cluster of differentiation 155 [CD155]) and human papillomavirus (HPV) status in primary tumors of penile cancer patients with indication for perioperative oncological treatment. As a secondary aim, we evaluated the associations between these biomarkers and penile cancer-specific survival. Methods: Fifty-two patients who underwent surgical treatment during 2009-2018 were included. HPV status was determined by polymerase chain reaction, and tissue microarray sections from primary tumors were subjected to immunohistochemistry to evaluate the expression of PD-L1, TIGIT, and CD155. Key findings and limitations: PD-L1, TIGIT, and CD155 were expressed widely. Specifically, 75% of patients had PD-L1-positive tumors, 80% had TIGIT-positive tumors, and 98% had CD155-positive tumors. Additionally, 47% of patients had HPV-positive tumors. Patients with HPV-positive tumors had better survival than those with HPV-negative tumors. Patients with indication for perioperative oncological therapy who received such treatment and whose tumors exhibited low PD-L1 expression demonstrated better survival than those with higher PD-L1 expression levels. The main limitations of this study include the small number of patients, retrospective design, and use of tissue microarrays rather than whole tissue sections. Conclusions and clinical implications: We found high expressions of the investigated checkpoint proteins, suggesting an immunosuppressed tumor microenvironment in patients with advanced penile cancer. These findings imply that checkpoint proteins could serve as prognostic and treatment predictive biomarkers. Patients with HPV-positive tumors had better prognosis. Patient summary: In this report, we investigated tumor tissue from patients with penile cancer and identified a high prevalence of proteins that play an important role in the immune system's defense against cancer. The findings suggest that these proteins can be important in understanding and developing treatments for patients with lymph node metastasized penile cancer.

Indexed as

CD155ChemotherapyHuman papillomavirusPD-L1Penile cancerRadiotherapyTIGITTumor microenvironment

Identifiers

PMID40822998
PMCPMC12357277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.